

Inborn Errors Working Party Annual Conference

Zurich, Switzerland | 25-27 September 2026



PRELIMINARY PROGRAMME – MAIN TRACK

Friday, 25 September 2026

13:00-13:45	Registration & Welcome Coffee	
13:45-14:00	Welcome from the organisers Maria Ester Bernardo (IT), Claire Booth (UK) and Tayfun Güngör (CH)	
14:00-16:00	Session 1 Allogeneic HSCT and HSC-GT for IEM Chairs: Giulia Consiglieri (IT)	
14:00-14:15	Biomarkers in ALD, Gene Therapy and Allo-HCT	Troy Lund (US)
14:15-14:30	Biomarkers on CSF in MLD	
14:30-14:45	Update on the MPS II clinical trial/immune response to transgene and assays	
14:45-15:00	Update on the MPS III clinical trial	
15:00-15:15	Real-world data for MLD	
15:15-15:30	Umbilical cord blood transplant outcomes in NMD in the modern era	
15:30-15:45	Platform approach for LSDs with skeletal and neurological involvement: clinical trial design	
15:45-16:00	Mechanisms of immune response after HSC-GT for metabolic diseases	
16:00-16:30	Coffee Break	
16:30-18:30	Session 2 CGD special session from mechanism to novel therapies Chairs: Tayfun Güngör (CH)	
16:30-16:55	EROS and new insights into CGD signaling pathways	David Thomas (UK)
16:55-17:15	Allo-HSCT	Tayfun Güngör (CH)
17:15-17:35	Biologics of chronic granulomatous disease	
17:35-17:50	Gene editing in HSC for correcting the oxidative burst in CGD	Giorgia Santilli (UK)
17:50-18:00	TBD	
18:00-18:10	TBD	
18:10-18:30	Panel Discussion	

Inborn Errors Working Party Annual Conference

Zurich, Switzerland | 25-27 September 2026



PRELIMINARY PROGRAMME – NURSES TRACK

Saturday, 26 September 2026

Session 1 | Care Team Challenges in Patient and Family Care

Welcome message

Challenges we face every day treating private and international patients

TBD

Improving information resources for informed consent conversations - project with the Gene Therapy families

TBD

Session 2 | Quality of Life and long-term outcomes

Welcome message

Post-GT experience in WAS patients with a focus on quality of life and long-term follow-up

TBD

TBD

Inborn Errors Working Party Annual Conference

Zurich, Switzerland | 25-27 September 2026



PRELIMINARY PROGRAMME – MAIN TRACK

Saturday, 26 September 2026

09:00-10:30	Session 3 HSC-Gene therapy for IEIs Chairs: Claire Booth (UK)	
09:00-09:15	Overview of current open trials	Claire Booth (UK)
09:15-09:25	Preclinical development of gene therapy for Major Histocompatibility Complex Class II (MHC II) Deficiency	
09:25-09:35	Gene editing for STASIS disorders	
09:35-09:40	International XIAP GT consortium	Claire Booth (UK)
09:40-09:50	CD40L moving to the clinic	Daniele Canarutto (IT)
09:50-10:00	P47 CGD LV clinical trial update	Jasmeen Dara (UK)
10:00-10:10	Artemis -SCID	
10:10-10:20	WASKYRA approval - current update about rollout/availability and results of EAS	
10:20-10:30	Initiatives and regulatory innovation to improve access to GT in Europe	
10:30-10:45	Coffee Break	
10:45-11:25	Keynote Lecture Epstein-Barr Virus, autoimmune disease & big data management Prof. Christian Münz (CH)	
11:25-12:10	Session 4 B cells and plasma cell derived treatments Chairs: Carsten Speckmann (DE) and Julian Thalhammer (DE)	
11:25-11:35	Pathology on early B cells defects	Mirjam van der Burg (NL)
11:35-11:45	HSCT experience in XLA	Andrew Gennery (UK)
11:45-11:55	B cell pathology in CVID	
11:55-12:10	Anti-CD19 CAR T cells refractory autoimmune disease	Franco Locatelli (IT)
12:10-13:00	Lunch Break	
13:00-14:15	Session 5 Thymus transplant Chairs:	
13:00-13:20	Rebuilding Immunity after Pediatric HCT: The Role of Thymic Hormones	Coco de Koning (NL)
13:20-13:40	Sex differences in the human thymus	
13:40-14:00	Two cases on Challenging referrals for thymic transplants	Coco de Koning (NL)
14:00-14:15	Discussions on the current state algorithm for decision-making	

Inborn Errors Working Party Annual Conference

Zurich, Switzerland | 25-27 September 2026



14:15-15:15 **Session 6 | Advances in GvHD and endothelial complications**

Chairs: Andrew Gennery (UK)

TBD

TBD

TBD

TBD

15:15-15:35 **Coffee Break**

15:35-16:15 **Keynote Lecture**

Immuno-conditioning for SCT and GT

Prof. Markus Manz (CH)

16:15-17:00 **Session 7 | Precision conditioning**

Chairs:

16:15-16:25 TDM Treo Flu

16:25-16:35 Biologicals could include an epitope editing talk

16:35-16:45 Cell (CAR) based conditioning

16:45-17:00 Panel discussion on conditioning approaches (one-size fits all vs MIPD vs TDM) for our current drugs

17:00-18:00 **Session 8 | Advanced diagnostics and treatment of infections**

Chairs:

17:00-17:20 Fungal infections in CGD: new antifungal drugs, indications for granulocyte transfusions as bridge to HSCT, when to transplant with an active fungal infection

17:20-17:35 When conventional antimicrobials are not enough: new antimicrobial drugs in HSCT, including antibacterials, antivirals (anti-HSV agents) and phage therapy

17:35-17:50 Atypical viral infections: Aichi virus

17:50-18:00 NGS case report with neurological involvement, case series from Necker's experience with NGS

Inborn Errors Working Party Annual Conference

Zurich, Switzerland | 25-27 September 2026



PRELIMINARY PROGRAMME – MAIN TRACK

Sunday, 27 September 2026

09:00-10:30	Session 9 Juniors session Management of IEIs in cases with unclear/inconclusive genetic findings Chairs: Sujal Ghosh (DE) Summary of the webinars held so far Newborn Screening and SCT indication Case Presentation 1 by IEWP junior committee member Case Presentation 2 by IEWP junior committee member Case Presentation 3 by IEWP junior committee member Interactive discussion (voting on management decisions among the audience) and Panel Discussion	
10:30-10:50	Coffee Break	
10:50-11:35	Session 10 IEWP Studies Chairs: Maria Ester Bernardo (IT) and Claire Booth (UK)	
10:50-11:00	DADA2 study	Juliana Silva (UK)
11:00-11:15	P-CID study	
11:15-11:25	FHL2/3 study	
11:25-11:35	CHH study	Helja Lång (FI)
11:35-13:05	Session 11 Advances in immune dysregulation Chairs:	
11:35-11:53	ADA2 updates, including management of patients with dominant negative disease	
11:53-12:11	Autophagy/inflammation in WAS	
12:11-12:29	STAT6 GOF updates on the current ESID registry study	
12:29-12:47	ZNFX1 update on current collaborative study	
12:47-13:05	NFKBIA clinical spectrum and HSCT strategies	Winnie Ip (UK)
13:05-13:15	Final Remarks Maria Ester Bernardo (IT), Claire Booth (UK), Tayfun Güngör (CH)	